Healthy adult
Conditions
Interventions
Daily ingestion two packets (2.5 g per packet) of test food 1 for 16 weeks.
Daily ingestion two packets (2.5 g per packet) of test food 2 for 16 weeks.
Daily ingestion two packets (2.5 g per packet) o
Sponsors
Hokkaido Information University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Those who agree to participate in this study with a written informed consent. 2. Those with BMI is >=23 kg/m2 and <30 kg/m2 at the time of screening.
Exclusion criteria
Exclusion criteria: 1. Subjects who are under physician's advice, treatment, and/or medication for obese, diabetes, and/or dyslipidemia. 2. Subjects with implantable electronic medical devices. 3. Subjects who have metal implants at the CT scan site. 4. Subjects with serious cerebrovascular, cardiac, hepatic, renal, gastrointestinal diseases, endocrine diseases and/or affected with infectious diseases requiring reports to the authorities. 5. Subjects with major surgical history relevant to the digestive system such as gastrectomy, gastrorrhaphy, enterectomy, etc. 6. Subjects with unusually high and/or low blood pressure and/or abnormal hematological data. 7. Subjects with severe anemia. 8. Pre- or post-menopausal women complaining of obvious physical changes. 9. Subjects who are at risk of having allergic reactions to drugs or foods. 10. Subjects who regularly take medicine, functional foods, and/or supplements which would affect obese and/or intestinal environment. 11. Subjects with oligosaccharide intolerance. 12. Subjects who changes in body weight of 10% or more within 12 wks prior to the screening. 13. Subjects whose lifestyle is planned to change during the study. 14. Heavy smokers, alcohol addicts or subjects with disordered lifestyle. 15. Subjects who donated either 400 ml whole blood within 16 wks (women), 12 wks(men), 200 ml whole blood within 4 wks (men and women), or blood components within 2 wks (men and women), prior to the screening. 16. Pregnant or lactating women or those planning to become pregnant. 17. Subjects who currently participate in other clinical trials, or participated within the last 4 weeks prior to the current study. 18. Any other medical and/or health reasons unfavorable to participation in the current study, as judged by the principal investigator.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Visceral fat area at 16 weeks after ingestion. | — |
Secondary
| Measure | Time frame |
|---|---|
| Total fat area, subcutaneous fat area, body composition, blood glucose, gut microbiota, short-chain fatty acids in feces, blood metabolome analysis. | — |
Countries
Japan
Contacts
Public ContactNaoyuki HONMA
Hokkaido Information University Health Information Science Center
Outcome results
None listed